D. Voliotis

22.6k citations
49 papers · 7.6k · 3 hit papers · h-index 20

Impact in

Papers in

D. Voliotis

48 papers receiving 7.5k citations

D. Voliotis's Hit Papers

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial 2012 · 661 citations
6610+7+14Years since publication10002.0k3.0k4.0k

Peers

D. Voliotis
Comparison fields: 5 of 101
  • Hepatology 4.2k
  • Pathology and Forensic Medicine 1.2k
  • Cancer Research 1.0k
  • Oncology 1.4k
  • Epidemiology 1.2k
Replace Gerold Meinhardt with:
Gerold Meinhardt United States
Jean‐Frédéric Blanc France
Ronnie Tung‐Ping Poon Hong Kong
Ghassan K. Abou‐Alfa United States
Chao-Jung Tsao Taiwan
재연 정
K. Burock United States
Zhongzhen Guan China
Tsai‐Sheng Yang Taiwan
Lorenza Rimassa Italy
D. Voliotis relative to Gerold Meinhardt United States Gerold Meinhardt's profile →
Citations per field
00.5×1.7×
Gerold Meinhardt · 1×
Citations per year

Countries citing papers authored by D. Voliotis

Since Specialization
Citations

This map shows the geographic impact of D. Voliotis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Voliotis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Voliotis more than expected).

Fields of papers citing papers by D. Voliotis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Voliotis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Voliotis. The network helps show where D. Voliotis may publish in the future.

Co-authors

The 25 scholars most cited alongside D. Voliotis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D. Voliotis Line = papers co-authored together D. Voliotis links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Hit paper breakdown →
20084666
2
Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors
Hit paper breakdown →
2004698
3
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Hit paper breakdown →
2012661
4 2005325
5 2012223
6 2007163
7 2006115
8 2012102
9 200292
10 200687
11
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.
201179
12 200845
13 200744
14 200538
15 200724
16 201022
17 200421
18 200321
19 202120
20 200820

About D. Voliotis

D. Voliotis is a scholar working on Hepatology, Molecular Biology, Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 49 papers that have together received 7.6k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (21 papers), Cancer, Lipids, and Metabolism (8 papers), Colorectal Cancer Treatments and Studies (7 papers), Lung Cancer Treatments and Mutations (7 papers), Melanoma and MAPK Pathways (6 papers), Cancer Mechanisms and Therapy (5 papers), Cancer Treatment and Pharmacology (4 papers) and Liver Disease Diagnosis and Treatment (4 papers). The work is most often cited by research in Hepatology (4.2k citations), Pathology and Forensic Medicine (1.2k citations), Cancer Research (1.0k citations), Oncology (1.4k citations) and Epidemiology (1.2k citations). D. Voliotis has collaborated with scholars based in Germany, United States and Taiwan. Frequent co-authors include Ann‐Lii Cheng, Yoon‐Koo Kang, Won Young Tak, Tsai‐Sheng Yang, Zhendong Chen, Zhongzhen Guan, Jianming Xu, Chao-Jung Tsao, Hongming Pan and Jun Suk Kim. Their work appears in journals such as Journal of Clinical Oncology, Journal of Hepatology, Annals of Oncology, European Journal of Cancer and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact